ameliorate

NS-3-008 hydrochloride (NS-3-008 HCl) is a transcriptional G0/G1 switch 2 (G0s2) inhibitor( IC50 of 2.25 μM).

Astramembrangenin (Cycloastragenol (Astramembrangenin)) is a triterpenoid saponin compound and a hydrolysis product of the main active ingredient in Astragalus membranaceus. Cycloastragenol (CAG) may have a novel therapeutic role in depression

3,4,5-Trimethoxybenzoic acid (Gallic acid trimethyl ether) are potent antioxidants and inhibitor of cytokine production. It can ameliorate chronic stress-induced various behavioral and biochemical alterations in mice. It also exerts hepatoprotective effects in CCl4-induced rats, specifically by modulating oxidative-nitrosative stress and inflammation.

Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.

5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.

1. Berberine (Umbellatine) is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism. 2. Berberine may as a broad-spectrum anti-microbial medicine, a complementary therapeutic agent for HIV/AIDS. 3. Berberine seems to act as an herbal antidepressant and a neuroprotector against neurodegenerative disorders. 4. Berberine is used in histology for staining heparin in mast cells. As a natural dye, berberine has a colour index of 7516. 5. Berberine reduces hepatic fat content in rats with nonalcoholic fatty liver disease; also prevents proliferation of hepatic stellate cells (HSCs), which are central for the development of fibrosis during liver injury. 6. Berberine can ameliorate proinflammatory cytokines-induced intestinal epithelial tight junction damage in vitro, and berberine may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states. 7. Berberine has antineoplastic effects, including breast cancer, leukemia, melanoma, epidermoid carcinoma, hepatoma, pancreatic cancer, oral carcinoma, tongue carcinoma, glioblastoma, prostate carcinoma and gastric carcinoma, etc.

AVE-9488 is a novel endothelial NO synthase (eNOS) enhancer that upregulates eNOS expression, induces NO production, and may ameliorate portal hypertension.

ML334 (LH601A) is a transmembrane and potent NRF2 activator that inhibits Keap1-NRF2 protein interactions to ameliorate myocardial infarction-induced cardiac fibrosis by inhibiting cardiac fibroblast activation and proliferation.

Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders.

Ipronidazole (RO-71554) is an orally effective antiprotozoal agent used to prevent and ameliorate histomoniasis in turkeys, commonly referred to as blackhead disease.

ADWX 1 TFA is a novel peptide that potently targets and inhibits the Kv1.3 channel, with an IC50 of 1.89 pM. It specifically suppresses the activity of the Kv1.3 channel, in addition to inhibiting initial calcium signaling and NF-κB activation. This compound has been shown to ameliorate symptoms in rats with experimental autoimmune encephalomyelitis (EAE). ADWX 1 TFA is utilized in research focused on T-cell-mediated autoimmune diseases.

(6S)-CP-470711 (Compound 8) acts as an inhibitor of sorbitol dehydrogenase (SDH) in both humans and rats, exhibiting inhibitory concentrations (IC50) of 19 nM and 27 nM, respectively. Additionally, (6S)-CP-470711 has been shown to ameliorate diabetes in rats induced by Streptozotocin.

FXR agonist10 (Compound 27) acts as an agonist for FXR with an EC50 of 14.26 μM. It increases the expression of SHP and BSEP proteins while decreasing the expression of NTCP and CYP7A1 proteins. Additionally, FXR agonist10 has been shown to ameliorate ANIT-induced cholestasis in mouse models.

NLRP3-IN-76 is an orally active NLRP3 inhibitor that suppresses the production of NO and reduces the mRNA levels of pro-inflammatory cytokines (iNOS, IL-6, IL-1β, and TNFα). It exerts anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and the NF-κB signaling pathway. Furthermore, NLRP3-IN-76 can ameliorate DSS-induced colitis and is applicable for studying inflammatory bowel disease (IBD).

α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor with an IC50 of 4.32 μM, demonstrating acute blood-glucose-lowering properties. It is safe and effective in vivo, showing no toxicity to normal fibroblasts in mice and can ameliorate diabetes induced by streptozotocin in rats. α-Glucosidase-IN-43 is applicable for research on postprandial hyperglycemia in diabetic patients.

NZ-97 is an inhibitor of dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. It exhibits low initial plasma exposure with a Cmax of 0.13 µM and is eliminated within 8 hours. NZ-97 can ameliorate lipopolysaccharides-induced lung injury and bleomycin-induced pulmonary fibrosis in mouse models.

PNSC928 is an inhibitor of the CtBP2-p300 interaction, with an IC50 of 23.60 µM. It can reverse the expression of pro-inflammatory cytokines induced by Lipopolysaccharides in RAW264.7 cells. Additionally, PNSC928 has the potential to ameliorate acute respiratory distress syndrome (ARDS) in mice.

VDR agonist 4 is a potent VDR agonist that is effective when administered orally. It exhibits VDR-dependent antifibrotic activity by modulating various fibrosis-related genes, thereby inhibiting the production of α-SMA and collagen I and suppressing the activation of hepatic stellate cells. VDR agonist 4 can ameliorate liver fibrosis in mice induced by CCl4 and is useful for research related to liver fibrosis.

FXR agonist14 (Compound V15) is a partial, selective, orally active FXR agonist with an EC50 of 0.67 nM. It can ameliorate the pathological features in mice with MASH induced by a high-fat, high-sugar diet, and shows significant effects against cholestatic liver disease.

Aβ aggregation-IN-3 (Compound B7) is an inhibitor of Aβ aggregation. It prevents the aggregation of Aβ and exhibits protective effects in both neuronal and microglial cell models. Additionally, Aβ aggregation-IN-3 alleviates Aβ-induced paralysis in Caenorhabditis elegans and can ameliorate symptoms associated with Alzheimer's disease.

LX2932 is an oral analog of LX2931 and acts as a modulator of the S1P/S1PR signaling pathway. It effectively decreases the number of circulating lymphocytes in a dose-dependent manner. Additionally, LX2932 has been shown to ameliorate collagen-induced arthritis.

ML-193 (CID 1261822) is a potent and selective GPR55 antagonist (IC50: 221 nM) with over 27-fold selectivity for GPR55 over GPR35, CB1, and CB2. It can ameliorate motor and sensorimotor deficits in Parkinson's disease (PD) rats.

BMS 199264 hydrochloride is the salt form of BMS 199264.BMS 199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase (IC50=0.5 μM) without affecting ATP synthetase, thus preventing ATP reduction to ameliorate cardiac necrosis during ischemia, and is commonly used in studies of the cardiovascular system.

Pronuciferine ameliorate the glucose and lipid metabolism in insulin-resistant 3T3-L1 adipocytes.